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Summary 
We used CD28-deficient mice to analyze the importance of CD28  costimulation for the re- 
sponse against Staphylococcal enterotoxin B  (SEB)  in vivo. CD28 was necessary for the strong 
expansion ofV[38 + T  cells, but not for deletion. The lack of expansion was not due to a failure 
of SEB  to activate VI38 + T  cells,  as V[38 + T  cells  from both CD28 -/-  and CD28 +/+  mice 
showed similar phenotypic changes within the first 24 h after SEB injection and cell cycle anal- 
ysis showed that an equal percentage ofV[~8 + T  cells started to proliferate. However, the phe- 
notype and the state of proliferation ofV[38 + T  ceils was different at later time points. Further- 
more, in CD28 -/- mice injection with SEB led to rapid induction of unresponsiveness in SEB 
responsive T  cells, indicated by a drastic reduction of proliferation after secondary SEB stimula- 
tion in vitro.  Unresponsiveness could also  be demonstrated in vivo, as  CD28 -/-  mice pro- 
duced only marginal amounts of TNFot after rechallenge with SEB. In addition CD28 -/- mice 
were protected against a lethal toxic shock induced by a second injection with SEB. Our results 
indicate that CD28 costimulation is crucial for the T  ceil-mediated toxicity of SEB and dem- 
onstrate that T  cell stimulation in the absence of CD28 costimulation induces unresponsiveness 
in vivo. 
S 
timulation  of the  T  cell  receptor  (TCR)  alone  is  not 
sufficient for optimal T  cell  activation.  Costimulatory 
signals  are required in addition for the induction  of maxi- 
mal T  celt response (1,  2,  3).  CD28  is probably the  most 
important  costimulatory molecule for T  cells.  Ligands for 
CD28 are B7-1  (CD80) and B7-2 (CD86), both expressed 
on B  cells,  activated monocytes, dendritic  cells,  and acti- 
vated T  cells (2). It has been shown that blocking the inter- 
action between CD28  and the B7 molecules with mono- 
clonal antibodies or with a CTLA-4-Ig fusion protein can 
abolish  T  cell  proliferation  in  vitro.  Furthermore,  the 
CTLA-4-Ig fusion  protein is  able  to  reduce  the  immune 
response in different in vivo models (reviewed in reference 
2), indicating that the interaction of CD28 with its ligands 
is crucial for a functional immune response. 
Mice deficient for CD28 contain normal numbers of pe- 
ripheral CD4 + and CD8 + T  cells (4). Positive and negative 
selection  appear  not  to  be  affected  in  either  normal  or 
TCR  transgenic  CD28 -/-  mice  (4,  5).  T  cells  from 
CD28 -/- mice show strong impairment of proliferation in 
vitro after stimulation  with  anti-TCR  antibodies  or con- 
canavalin A, after allostimulation, and after antigen specific 
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stimulation  (4,  5,  6).  CD28 -/-  mice  have normal  serum 
levels of IgM but reduced levels of serum IgG1, indicating 
that T  helper function,  important for Ig class switching,  is 
impaired.  Consistent  with  this,  CD28 -/-  mice  produce 
normal  amounts  of neutralizing  IgM  after infection with 
Vesicular  Stomatitis  Virus,  a  response  known  to  be  T 
helper  cell independent,  but  reduced levels  of IgG, a  re- 
sponse which is T  helper cell dependent (4).  Interestingly, 
the response against Lymphocytic Choriomeningitis Virus 
is not affected in CD28 -/- mice. CD28 therefore seems to 
be differentially required  for T  cell responses and alterna- 
tive costimulatory pathways may exist (4). 
Bacterial  superantigens  (BSAg) 1 are  bacterial  exotoxins 
secreted by staphylococci,  streptococci and  other bacteria 
(7,  8).  BSAg bind to MHC  class II molecules (9)  and the 
MHC class II-BSAg complex interacts with the TCR and 
induces T  cell activation (7,  8,  10).  In contrast to lectins, 
BSAg  display  specificity  for  the  variable  domain  of the 
TCR  [3 chain and activate only T  cells that express certain 
TCR  13  chains  (11,  12).  Furthermore,  T  cell  stimulation 
seems to be independent  of CD4  and CD8,  since  cells  of 
t  Abbreviations used in this paper: BSAg, bacterial superantigen; SEA, staphylo- 
coccal enterotoxin A; SEB, staphylococcal  enterotoxin B. 
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class II complex (13). The in vivo effects of BSAg, especially 
of some of the staphylococcal enterotoxins (Staphylococcal 
enterotoxin  A  and  B,  Toxic  Shock  Syndrome  Toxin-I), 
are well analyzed. Injection of BSAg induces strong T  cell 
responses  in  vivo.  A  single injection leads to  massive  ex- 
pansion of T  cells with responsive TCP,  Vl3-elements, that 
peaks at day three, followed by deletion at day 5-7, which 
lasts  for  several  weeks  (14,  15,  16).  At  these  later  time 
points  T  cells  are  in  a  state  of unresponsiveness,  as  they 
don't proliferate after stimulation with the particular BSAg, 
in spite of expressing a TCl'Z [3 chain that can interact with 
the BSAg (14,  17,  18). 
In  this study we  have  analyzed the  response  of T  cells 
against  the  BSAg  SEB  in  mice  lacking CD28  and  found 
CD28  necessary  for  the  expansion  of SEB  responsive  T 
cells but  not  for  the  deletion of this T  cell population in 
vivo. T  cells of both CD28 -/-  and CD28 +/+ mice showed 
the same phenotypic changes within the first 24 h  after in- 
jection  of SEB,  but  were  different  in  their  phenotype  at 
later time points.  In addition,  cell cycle analysis indicated 
that after 24 h an equal percentage ofV~8 + T  cells are pro- 
liferating in CD28 +/+ and CD28 -/-  mice, whereas at later 
time points CD28 -/-  mice showed a  drastic reduction in 
the  proliferation of this  T  cell population,  indicating that 
CD28  costimulation was not essential for the initial T  cell 
stimulation with SEB. Furthermore, in CD28 -/-  mice, in- 
jection of SEB  led to  the induction of anergy in  SEB  re- 
sponsive T  cells within 24 h, which was reflected by a fail- 
ure  of proliferation after restimulation with  SEB  in  vitro 
and by a diminished TNFcx production after a rechallenge 
with SEB in vivo. In addition, CD28 -/-  mice did not suc- 
cumb to lethal toxic shock after a second SEB injection. 
Materials  and Methods 
Animals and Reagents.  BALB/c mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME).The generation of CD28 -/- 
mice is described elsewhere (4). CD28 -/- mice were back crossed 
into the BALB/c strain for four generations and screened for the 
expression of H-2k  a, H2-k  b and CD28 by flow cytometry. Mice 
were used at 7-10 wk of age. 
Staphylococcal enterotoxin A (SEA) and staphylococcal entero- 
toxin B (SEB; both Sigma Chem. Co., St. Louis, MO) were dis- 
solved in sterile phosphate buffered saline (PBS) at 1 mg/ml and 
further dilutions were done in sterile PBS. Mice were injected i.p. 
with the indicated amount of SEA or SEB in 100--200 ~1 of PBS. 
Flow cytometry.  The  following mAbs were used: FITC-con- 
jugated anti-H2-k  b (clone: AF6-88.5), FITC-conjugated anti-H2-k  a 
(clone:  SF1-1.1),  FITC-  and  PE-conjugated  anti-TCgV[38.1, 
8.2  (clone: MR.5-2),  FITC- and PE-conjugated anti-TC1LV[36 
(clone:  ILR.4-7),  PE-conjugated anti-CD3e  (clone:  145-2Cll), 
biotin-conjugated anti-CD8ct  (clone 53-6.7),  FITC-conjugated 
anti-CD25 (clone: 7D4), PE-conjugated anti-CD28 (clone: 37.51), 
FITC-conjugated anti-CD69  (clone:  H1.2F3)  (all PharMingen, 
San  Diego,  CA),  FITC-  and  PE-conjugated  anti-CD4  (clone: 
YTS191.1)  and  FITC-  and  PE-conjugated  anti-CD8  (clone: 
YTS169.4)  (Cedarlane Laboratories, Hornby, Canada). 
Mice were bled from the tail and 20 btl of  blood was collected in 
heparinized capillary tubes (Baxter Healthcare Corp., Deerfield,  IL). 
Blood was further diluted with 100 }xl of PBS containing 20 mM 
EDTA. Saturating amounts of mAb were added and the cells were 
incubated at 4~  for 30 min. Erythrocytes were lysed by the addi- 
tion of 1 nil of ammonium chloride solution and cells were washed 
twice with PBS and fixed with 1% parafom~aldehyde in PBS. 
Spleen and lymph node cells were prepared according to stan- 
dard procedures. Cells (5 X  10  s) were incubated in staining buffer 
(PBS,  l%  bovine  serum  albumin,  0.1%  NAN3) with  saturating 
amounts of mAbs for 30 min at 4~  Cells were washed twice in 
cold  staining  buffer  and  resuspended  in  PBS  containing  1% 
paraformaldehyde.  Cells stained with biotinylated mAb were washed 
twice with staining buffer, incubated with saturating amounts of 
Streptavidin-670 (GIBCO BRL,  Gaithersburg, MD) for 30 rain 
at  4~  washed  twice  with  staining buffer  and  fixed with  1% 
paraformaldehyde in PBS. A total of 10,000  viable cells were ana- 
lyzed using a  FACScan  |  flow  cytometer and  Lysis II  software 
(Becton Dickinson, Mountain View, CA). 
Cell Cycle Analysis.  4 X 10  ~' lymph node cells were stained with 
saturating amounts  of either  FITC-conjugated anti-VI38.1,  8.2 
mAb or FITC-conjugated anti-V[36  mAb, incubated for 30 min 
on ice and washed twice with R.PMI  1640  medium. Cells were 
resuspended in 1 ml of FCS and 1 nfl of RPMI 1640 medium was 
added. Cells were fixed by slowly adding 6 ml of ice-cold ethanol 
(70%  in  H20 ).  After incubating for  30  rain  at  4~  cells  were 
washed with PBS and resuspended in  100  ml PBS  containing 5 
txg/nil la,  NAse (Sigma).  Cell suspensions were further diluted by 
the addition of 900 ml of PBS containing 50 mg/ml propidium 
iodine (Sigma) and incubated for 30 min at 4~  DNA content of 
V~6 + and VI38.l, 8.2 + T  cells as revealed by the uptake ofpro- 
pidium iodine was analyzed by flow cytometry within 3 h. 
Proliferation Assay.  Lymph  node  cells (1  X  10  s)  were  incu- 
bated in  96-well round-bottom  plates (Nunc,  Kamptrop,  Den- 
mark) in 200 Ixl of ilL-1 medium (Hycor Biomedical Inc., lrvine 
CA) supplemented with 2 mM glutamine, 50  IxM 13-mercapto- 
ethanol, penicillin,  and streptomycin, and 2%  fetal bovine serum. 
Cells were stimulated by the addition of 5 txg/ml SEB or 50 U/ 
ml  recombinant mouse  IL-2  (Genzyme,  Cambridge, MA).  For 
stimulation with  cross-linked anti-CD3  antibodies, plates were 
coated  with  polyclonal rabbit anti-hamster antibodies  (Jackson 
Laboratories) at 10 ixg/ml in PBS at 4~  over night. Plates were 
washed with  PBS  and incubated for 3  h  with  anti-CD3e  mAb 
(clone:  145-2Cll; PharMingen) at 1 btg/ml in PBS and washed 
again with PBS.  After the indicated rime of culture,  1 IxCi/well 
[3H]thymidine (NEN, Boston MA) was added to the cell cultures 
and after additional 12-18 h cells were harvested (Filtem~ate-196 
harvester; Canberra Packard, Mississauga Canada) and [3H]thymi- 
dine  incorporation determined  (Matrix-96 direct beta  counter, 
Canberra Packard). 
TNFee ELISA.  Peripheral blood of mice was collected in se- 
rum separator tubes (Becton Dickinson). Tubes were centrifuged 
for 10 min and the sera were collected and stored at -70~  Sera 
were diluted 1/2 and 1/4 in PBS and TNF0~ was determined by 
ELISA (Genzyme, Cambridge, MA) according to the manual of 
the manufacturer. 
Results 
SEB  Fails  to Induce  a  Strong  Expansion  but  Leads  to Early 
Deletion of V~88.1, 8.2  + T  Cells in CD28 -/- Mice.  CD28 +/+ 
and CD28 -/-  mice were injected with 100 ~g of SEB and 
the absolute numbers  ofV[38.l,  8.2 + and V[36 + T  cells in 
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injection (Fig. 1). VI38.1 and V138.2 are two variable TCRI3- 
elements that are recognized by SEB and V136 is a variable 
TCRl3-element  that  is  not.  In  CD28+/+  mice  CD4 + 
VI38.1, 8.2 + and CD8 + V138.1,  8.2 + T  cells showed a strong 
increase in cell number at day 3, which was due to both an 
increase in the percentage ofV[38.1, 8.2 + T  cells and in the 
cellularity of the  spleen  (data  not  shown).  At  day  7  the 
numbers  of both  CD8 +  V138.1,  8.2 +  and  CD4 +  V[38.1, 
8.2 + T  cells were comparable to the numbers in untreated 
animals and at day 14 both populations showed deletion. In 
contrast,  CD28 -/-  mice  displayed  no  expansion  in  the 
numbers  of either  CD4 +  V[38.1,  8.2 +  or  CD8 +  V138.1, 
8.2 + T  cells at day 3. At day 7  cell numbers of both popu- 
lations were already lower than corresponding numbers in 
untreated mice, and at day 14 a deletion comparable to that 
in  CD28 +/+  mice  had  occurred.  In  both  CD28 +/+  and 
CD28 -/-  mice, the numbers of V[36 + T  cells showed only 
subtle changes during this time period. 
The analysis of the percentages of V[38.1,  8.2 + and V136 + 
T  cells in the peripheral blood of mice injected with SEB 
led  to  similar results,  confirming  the  impaired expansion 
and fast deletion of V[38.1,  8.2 +  T  cells in CD28 -/-  mice 
compared to CD28 +/+ mice (data not shown). 
SEB Activates  Vfl8.1,  8.2  + T  Cells in CD28  -/-  Mice.  The 
lack of expansion of SEB  responsive T  cells could reflect a 
failure of SEB to activate T  cells in CD28 -/-  mice. To de- 
termine the extend ofT  cell activation, mice were injected 
with  SEB  and lymph node  T  cells were analyzed by flow 
cytometry  for  cell  size  and  the  expression  of activation 
markers  (Fig.  2).  24  h  after  SEB  injection,  most  of the 
V[38.1,  8.2 + T  cells in both CD28 -/-  and CD28 +/+  mice 
were blasts. After 48  h  the average size of V[38.1,  8.2 +  T 
cells  in  CD28 +/+  mice  was  decreased,  but  the  majority 
were still blast cells. In contrast, in CD28 -/-  mice V[38.1, 
8.2 + T  cells were small, and only a few V[38.1,  8.2 + T  cell 
blasts were visible at 48 h  (11.7% compared to 77.7% in the 
CD28 +/+ mice). 
The surface molecule CD69  is upregulated early after T 
cell  activation.  24  h  after  SEB  injection  CD69  was  ex- 
pressed both in CD28 -/-  and CD28 +/+  mice on virtually 
all V138.1, 8.2 + T  cells. After 48 h  most of the V[38.1, 8.2 + 
T  cells in CD28 -/-  mice were  CD69-  whereas  CD28 +/+ 
mice still had a significant CD69 + V[38.1, 8.2 + T  cell pop- 
ulation  (15.4%  in CD28 -/-  mice and  47.8%  in CD28 +/+ 
mice). 
The or-chain of the IL-2P,. (CD25)  represents another T 
cell  activation  marker.  In  untreated  mice  only  a  minute 
portion of VI38.1, 8.2 + T  cells were CD25 +. At 24 h  after 
SEB injection, the majority of VI38.1,  8.2 + T  cells in both 
CD28 -/-  and CD28 +/+ mice were CD25 +. However, ac- 
tivated T  cells in CD28 -/-  mice expressed a  10-fold lower 
amount of CD25. After 48 h  almost all V138.1,  8.2 + T  cells 
in the CD28 -/-  mice were CD25-.  In contrast, CD28 +/+ 
mice displayed still a significant CD25 + VI38.1, 8.2 + T  cell 
population  (5.2%  in  CD28 -/-  versus  31.3%  in  CD28 +/+ 
mice). V136 +  T  cells showed  no  significant changes in  ei- 
ther cell size or expression of activation markers during the 
observed period (data not shown). 
Blast transformation indicated that the V[38 + T  cells had 
started to proliferate. To prove that this really was the case 
we did cell cycle analysis of V138 +  and V136  +  T  cells after 
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Figure 1.  SEB fails to induce 
expansion  of  V[38.1,  8.2 +  T 
cells, but  leads to  deletion  of 
these  cells  in  the  spleen  of 
CD28 -/- mice. Mice  were  in- 
jected  intraperitoneal  with  100 
Ixg SEB. After the indicated time 
periods  mice  were  killed  and 
numbers of spleen cells were de- 
termined.  Spleen  cells were 
stained  with  FITC-conjugated 
anti-CD4 or anti-CD8 mAbs and 
with  PE-conjugated  anti-VI36 
or anti-VI38.1, 8.2 mAbs and an- 
alyzed by flow cytometry.  Cell 
numbers  were  calculated from 
the total number of spleen cells 
and the percentages of the differ- 
ent  cell  populations.  Each  bar 
represents  the  mean  value  of 
three mice. 0  h  24  h  48  h 
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Figure  2.  SEB is able to activate VI38.1, 8.2 + T  cells in vivo. Mice were 
injected  i.p. with 100  txg SEB and killed after 24 and 48 h. Pooled bra- 
chial, axillary, and inguinal lymph node cells were stained with PE-conju- 
gated anti-V[36 or anti-VI38.1, 8.2 mAbs and with FITC-conjugated anti- 
CD69 or anti-CD25  mAbs and analyzed by flow cytometry using a gate 
for viable cells. 
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Figure  3.  Induction of proliferation of VI38.1,  8.2 + T  cells by SEB in 
vivo.  Mice were injected  intraperitoneal with  100  Ixg SEB and killed  at 
the  indicated  time points.  Pooled  brachial,  axillary,  and  inguinal lymph 
node cells were stained with FITC-conjugated  anti-V~6  or anti-VI38.1, 
8.2  mAbs, fixed with ethanol and  the DNA  content was analyzed  after 
propidium iodine staining by flow cytometry using a gate for viable VI36  + or 
VI38.1,  8.2 +  T  cells.  The  experiment  shown  is  representative  of two 
independent  experiments.  Black bars, %  VI36  +  or  VI38.1,  8.2 +  T  cells 
in S-phase; dotted bars, % VI36  + or V138.1,  8.2 + T  cells in G2-phase or mi- 
tosis. 
cling VI38 + T  cells in CD28 -/-  mice was already decreased 
at 48  h  and almost at the level of untreated mice at 72  h. 
The V136 + T  cells showed only minimal induction of pro- 
liferation throughout the entire observation period. 
In  summary,  SEB  was  able  to  activate  VI38.1,  8.2 +  T 
cells in both CD28 -/-  and CD28 +/+  mice, as determined 
by an increase in cell size and expression of the activation 
markers CD69 and CD25.  In addition, in both mice strains 
an  equal percentage  of VI38.1,  8.2 +  T  cells had started to 
proliferate. However, at 48 h  almost all activated T  cells in 
CD28 -/-  mice  had  returned  to  a  small,  CD25-  CD69- 
phenotype, whereas a significant proportion of VI38.1, 8.2 + 
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injection of SEB  (Fig. 3).  In untreated  mice  only a  small 
fraction of both VI36 + and V138 + T  cells were in S- or G2- 
phase or in mitosis. 24 h  after SEB injection ,'-,30% of the 
V138 + T  cells in both CD28 +/+  and CD28 -/-  mice had a 
hyper-diploid DNA  content.  In CD28 +/+  mice this T  cell 
population was further increased to almost 40% at 48 h  and 
back to ,--,10% at 72  h.  In contrast,  the percentage of cy- 
day 
Figure 4.  Proliferative response ofT cells from CD28 +/+ and CD28 -/- 
mice to SEB in vitro. Lymph node cells (1  ￿  10S/well) were incubated in 
medium alone (circles)  or in medium containing 5  I~g SEB/ml (triangles). 
[3H]thymidine was added at the time points indicated and cells were har- 
vested after additional  18 h. Each data point represents the mean value of 
triplicates.  White  symbols,  CD28 +/+  lymph  node  cells;  black symbols, 
CD28 -/- lymph node cells. 
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This difference was also reflected in the reduced number of 
proliferating cells  after  48  h.  Similar phenotypic  changes 
were also seen after injection of 20 Ixg of SEB and in splen- 
ocytes (data not shown). 
Early  Onset of Unresponsiveness  against  SEB in  CD28  -l- 
Mice.  The  different  activation  patterns  prompted  us  to 
analyze the responsiveness ofT  cells at different time points 
after  SEB  injection.  In  in  vitro  assays  CD28 -/-  and 
CD28 +/+  T  cells  displayed  equivalent  proliferation  after 
SEB  stimulation  during  the  first  48  h,  but  at  later  time 
points CD28 -/-  T  cells showed markedly decreased prolif- 
eration compared to CD28 +/+ T  cells (Fig. 4). 
Mice were injected with SEB and the in vitro response 
of lymph node T  cells to SEB and IL-2 was determined at 
24,  48  and 72  h  after SEB  injection (Fig. 5).  Proliferation 
was  measured  48  h  after  the  start  of the  culture.  At  this 
time  point  any  difference  in  the  proliferative  response 
should reflect a  difference in the state of responsiveness of 
the T  cells in vivo and not a difference of the in vitro pro- 
liferation  capacity  between  CD28 +/+  and  CD28 -/-  T 
cells. 
T  cells from CD28 -/-  and CD28 +/+ mice without prior 
exposure to SEB had a similar proliferative response to SEB 
in vitro. One day after SEB injection, T  cells from CD28 +/+ 
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Figure  5.  Early onset of unresponsiveness against SEB in CD28 -/- 
mice. Mice were injected intraperitoneal with 100 I~g SEB 3, 2, and 1 d 
before the in vitro assay.  Mice were killed and 1 X 105 lymph node cel/s/ 
well were incubated with the indicated stimuli (SEB: 5 ~g/ml, IL-2:50 
U/ml and plate bound anti-CD3e mAb). After 48 h cells were incubated 
with [3H]thymidine and harvested after additional 18 h. Each data point 
represents  the  mean  value  of triplicates.  White  bars, CD28 +/+  without 
stimulus; striped  bars, CD28 -/-  without  stimulus; dotted  bars, CD28 +/+ 
with indicated stimulus; black bars, CD28 -/- with indicated stimulus. 
mice  displayed an  increase in  the  in  vitro  SEB  response. 
But  this  effect reverted within  the following 48  h  and T 
cells became unresponsive  at 72  h  after SEB  injection.  In 
contrast, at 24 h  after SEB injection T  cells from CD28 -/- 
mice  had  already lost their  ability to  respond  in  vitro  to 
SEB and remained in this state at 48 and 72 h. 
T  cells  from  untreated  CD28 -/-  and  CD28 +/+  mice 
showed some proliferation when incubated with  IL-2. At 
24 h  after SEB injection both cell populations displayed an 
increased response to IL-2 which decreased at 48 and 72 h. 
Overall, cells from CD28 -/-  mice had a lower response to 
IL-2, which corresponded to the lower expression level of 
IL-2R.cx/CD25  (Fig.  3  for 0,  24  and  48  h;  and  data  not 
shown for 72  h).  Stimulation with SEB in the presence of 
IL-2 resulted in similar proliferation of T  cells from both 
CD28 -/-  and  CD28 +/+  mice.  The proliferative response 
to anti-CD3 mAb showed no drastic changes, indicating that 
the changes seen in the proliferation to SEB were restricted 
to the SEB-responsive T  cell population. 
CD28  -/- Mice are Resistant  to Lethal Toxic Shock Induced by 
a Second SEB Injection.  To analyze the secondary response 
against SEB  in vivo, mice  were  injected with  100  Ixg of 
SEB  and rechallenged with the same SEB dose after 48 h. 
After the primary injection both  CD28 -/-  and  CD28 +/+ 
mice showed signs of illness (rough fur and decreased mo- 
bility).  Both  strains  usually  recovered  well  and  had  a 
healthy  appearance  by  48  h.  The  rechallenge  with  SEB 
48 h  after the primary injection had  a  profound effect on 
CD28 +/+  mice, as all animals displayed severe signs of ill- 
ness and were  dead or moribund after a further period of 
24 h  (Table 1.)  In contrast, all CD28 -/-  mice survived the 
SEB rechallenge and had a healthy appearance. 
CD28  -/-  Mice Produce only Low Amounts  of TNFa after 
Rechallenge with SEB.  One of the mediators of SEB induced 
toxic shock is TNFot. SEB induces high TNFot serum levels 
that peak 1 to 2  h  after injection and are produced mainly 
by T  cells (20,  21).  To analyze the TNFe~-production we 
injected mice with SEB  and rechallenged them with  SEB 
or SEA 48  h  after the primary injection. 90  min after the 
Table 1.  CD28 -/- Mice Are Resistant to Lethal Toxic Shock 
Induced by a Second SEB Injection 
SEB injection 
Day 0  Day 2  Dead/group no. 
CD28 -/-  --  100 lag  0/6 
100 p~g  100 p~g  0/6 
CD28 +/+  --  100 ~g  0/6 
100 p~g  100 big  5/6* 
Mice were injected i.p. with 100  I~g SEB and rechallenged with the 
same dose of SEB after 48 h. Numbers represent data from two inde- 
pendent experiments with three  mice per group  in each experiment. 
No. survival was scored 24 h after the second SEB injection. 
*The one mouse alive after 24 h was moribund and therefore killed. 
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Figure 6.  CD28 -/  mice pro- 
duce  only  low  amounts  of 
TNFe~  after  rechatlenge  with 
SEB. CD28 +/+ mice (dotted bars) 
and  CD28 -/-  mice  (black  bars) 
were  injected  intraperitoneal 
with 100 ~g SEB in 100 l.tl PBS 
or with  PBS alone, and rechal- 
lenged after 48 h with either 100 
Dg of SEB (top) or with 20 Dg of 
SEA (bottom).  Mice were  killed 
after  further  90  rain  and  sera 
were collected. Sera were diluted 
1/2 and 1/4 and TNF~x was de- 
termined  by  ELISA. Each  bar 
represents  the  mean  value  of 
three mice. 
primary SEB injection both CD28 -/-  and CD28 +/+  mice 
had comparable amounts of TNFot in the serum (Fig. 6).  It 
seemed therefore that CD28  was not necessary for the in- 
duction of TNF~x in a primary in vivo response. After the 
rechallenge with  SEB,  CD28 +/+  mice  had  serum  TNF(x 
levels comparable to the levels after the primary injection. 
In contrast, CD28 -/- mice produced only marginal amounts 
of TNFot. After SEA injection both CD28 +/+ and CD28 -/- 
mice  produced  equal  amounts  of TNFcx,  and  this  TNFcx 
production was not affected by the pretreatment of the mice 
with SEB. 
Discussion 
In CD28 +/+ mice, SEB induced strong expansion of both 
CD4 +  V[38 +  and  CD8 +  V~8 +  T  cells in peripheral lym- 
phoid organs,  whereas  CD28 -/-  mice failed to  show  this 
strong expansion. Closer examination revealed that the lack 
of expansion was not simply due  to  the failure of SEB  to 
stimulate this cell population. Injection of SEB induced sim- 
ilar phenotypic changes ofV~8 + T  cells in both CD28 -/- 
and CD28 +/+  mice. After 24 h  equal percentages of V[38 + 
T  ceils were blast cells, expressed the early T  cell activation 
marker  CD69,  and  more  important  an  equal  number  of 
V[38 + T  cells had entered the cell cycle. In CD28 +/+ mice, 
a significant proportion of V[38 + T  cells retained this acti- 
vated  proliferating phenotype  after  48  h,  whereas  only  a 
few  of those  ceils could be  detected in  CD28 -/-  mice  at 
this time point. It seems that stimulation of T  cells by SEB 
in the absence of CD28  costimulation leads to T  cell acti- 
vation,  but  this  T  cell activation is not  maintained  com- 
pared to the activation in the presence of CD28, and there- 
fore  does  not  support  the  large  expansion  of  SEB 
responsive T  cells seen  in  CD28 */+  mice.  This  result re- 
sembles the differences seen in proliferation after SEB stim- 
ulation in vitro (Fig. 4).  It is also in accordance with pub- 
lished  results  from  in  vitro  proliferation  assays,  where  T 
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cells from  CD28 -/-  mice showed a strong impairment in 
their proliferative response after stimulation with allogenic 
cells or with  peptide antigen  (5,  6).  In these  experiments 
the initial response of CD28 +/+  and CD28 -/-  T  cells was 
similar, but  the proliferation of CD28 -/-  T  cells was  not 
sustained. An important reason for this difference was  the 
low amount oflL-2 produced by CD28 -/-  T  cells in these 
assays, which is probably also a reason for the lack of T  cell 
expansion seen after SEB  injection in our in vivo experi- 
ments.  In summary,  CD28  costimulation is not  necessary 
for the initial phase of T  cell activation, but is essential for 
ongoing proliferation in  vitro  and,  as  demonstrated  here, 
after T  cell stimulation with SEB in vivo. 
Interestingly, SEB was able to induce peripheral T  cell de- 
letion in both CD28 +/+ and CD28 -/-  mice. CD28  there- 
fore is not necessary for the induction of the program that 
leads to deletion ofT  cells after their activation (37). CI)28 
costimulation has rather a protective function for activated 
T  cells since CD28 -/-  mice showed an earlier onset of de- 
letion.  It has  been  shown  that  T  cell stimulation induces 
expression of the Bcl-xL molecule which is able to protect 
cells from apoptosis and that CD28 costimulation enhances 
Bcl-xL  expression  (22).  In  addition,  CD28  costimulation 
leads to an increase in the transcription and the stabilization 
of IL-2  mRNA  and  therefore  to  an  increased  and  pro- 
longed IL-2 production  (23,  24,  25),  which  has also been 
demonstrated for T  cell stimulation with SEB in vitro (26). 
IL-2 supports the proliferation and expansion ofT cells and 
has in addition a protective function against apoptosis (27). 
Furthermore, it has been postulated that TCR. ligand den- 
sity and affinity is important for the dependence of T  cells 
on  CD28  costimulation (3).  During  the in vivo responses 
against allogenic and virus infected cells, where  antigen is 
present for several days and leads to  continuous  activation 
of T  cells, TCR  stimulation alone is probably sufficient to 
induce  mechanisms  that  support  proliferation and  protect 
activated T  cells from apoptosis, therefore leading to nor- 
real responses even in the absence of CD28  costimulation. 
In  our  system  SEB  is  injected  only  once  and  is  cleared 
within  a  short period of time.  T  cells are  therefore  con- 
fronted with a short period of high ligand density followed 
by a rapid decline of the ligand concentration. The mecha- 
nisms which protect T  cells from apoptosis and prolong the 
lifetime of T  cells after T  cell activation are therefore espe- 
cially challenged. The  lack of CD28  must necessarily lead 
to the aborted proliferation and the early onset of deletion 
ofT  cells seen in CD28 -/-  mice. 
In spite of the similarities in the phenotype, there was a 
striking  difference  between  T  cells  from  CD28 +/+  and 
CD28 -/-  mice  24  h  after  SEB  injection.  V[38 +  cells  in 
CD28 -/-  mice were already unresponsive to a rechallenge 
with SEB. Induction of unresponsiveness by SEB is a well- 
analyzed phenomenon.  It has been shown that after the ini- 
tial proliferation after SEB  injection,  T  cells enter a  state, 
where  they fail to proliferate to subsequent  SEB  exposure 
(14,  15,  17,  18).  Our results confirm these observations, as 
we saw a strong reduction of the in vitro proliferation of T 
cells from CD28 +/+  mice 72 h  after SEB injection. T  cells 
In Vivo Response of CD28-deficient Mice to Staphylococcal Enterotoxin B from CD28 -/-  mice were already unresponsive  24 h  after 
injection.  The addition  of IL-2 could rescue  the  response 
confirming that the T  cells are anergic. Interestingly, V~8 + 
T  cells of both CD28 +/+ and CD28 -/- mice had the same 
phenotype 24 h after SEB injection. Therefore, the state of 
unresponsiveness  did not correlate with the  appearance  of 
T  cells  and  was  not  restricted  to  resting  T  cells  as  at  this 
time  point  most  of the  V138  +  T  cells  in  CD28 -/-  mice 
were blasts and a significant proportion in cell cycle. Since 
T  cells from both CD28 +/+ and CD28 -/- mice respond to 
IL-2 or SEB  and  IL-2,  the  lower  expression  level  of IL- 
2II,0~/CD25  was  probably not responsible  for the  anergy. 
Our in vivo data resemble  initial  in vitro results,  where it 
was shown that T  cell stimulation  via TCR  in absence of 
costimulation leads to induction of anergy that can be pre- 
vented by CD28 costimulation (28, 29, 30). 
An important  question was,  whether  the  unresponsive- 
ness seen in vitro had also relevance in vivo. We addressed 
this question by rechallenging CD28 -/- mice with SEB 48 h 
after  the  primary  injection.  The  result  was  striking.  All 
CD28 +/+  mice  were  dead  or  moribund  within  24  h, 
whereas CD28 -/-  mice did not even show signs of illness. 
It has been shown that T  cells are responsible for the SEB 
induced toxicity mainly by the production of large amounts 
oflFN',/and TNFo~ ( 20, 21, 31, 32). At a later phase of the 
SEB  response,  TNFot  is  also  produced  by  macrophages 
(21).  It has been described  that  CD28 costimulation  of T 
cells leads to an increase in the production of certain lym- 
phokines,  including TNFci and IFN~/ (23,  24).  We there- 
fore can not exclude that lower or not maintained produc- 
tion of cytokines at both injections was responsible for the 
protection of CD28 -/- mice against lethal toxic shock after 
the  SEB  rechallenge.  However,  with  the  SEB  dose  used, 
both CD28 -/-  and CD28 +/+ mice showed the same signs 
of illness  after the first injection. But after the second injec- 
tion CD28 -/- mice showed no signs of illness  at all.  In ad- 
dition, we could not observe a difference in the serum lev- 
els  of TNFoe  90  rain  after  the  primary  SEB  injection, 
which represents the peak of T  cell TNFIx production (20, 
21). But we detected a difference after the rechallenge with 
SEB.  At  this  time  point  the  number  of VJ38 +  T  cells  in 
CD28 -/-  mice was roughly the same as that after the initial 
SEB injection. Thus, in vivo unresponsiveness ofT cells of 
CD28 -/-  mice  might  account  for  the  decrease  in  the 
TNF~x production. 
Another question raised is,  why did we see this fast in- 
duction of unresponsiveness after SEB injection in CD28 -/- 
mice,  whereas  the  response  against  allogenic  or virus  in- 
fected  cells  was  not  impaired  (3,  4)?  One  explanation  is 
probably the same as that for the aborted proliferation. SEB 
is cleared rapidly from the organism and therefore does not 
induce continuous T  cell stimulation.  An alternative possi- 
bility is that SEB as a superantigen does not have to be pro- 
cessed and is probably presented by different cells and in a 
different  environment  than  peptide  antigens.  Other  co- 
stimulatory molecules that can compensate for the lack of 
CD28  costimulation  (33,  34,  35,  36)  are  therefore  not  as 
efficiently triggered as in the response against antigens pre- 
sented by professional antigen presenting cells. 
In summary, our results show that CD28 is not necessary 
for T  cell activation by SEB in vivo and for subsequent de- 
letion.  However, in absence ofCD28 costimulation, T  cell 
activation can not be maintained and does not support the 
vast expansion ofVl~8 + T  cells  seen in CD28 +/+ mice.  In 
addition,  SEB  stimulation  of T  cells  in  absence'of CD28 
costimulation leads  to rapid induction of unresponsiveness 
in vivo. 
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